The advent of a novel category of oral ESAs have been assessed as a new therapeutic agent for anemia management in non-DX CKD ptns.
: Roxadustat for therapy of anemia in non-DX CKD ptns (April 2021).
Furthermore, compared with placebo, roxadustat has induced in the requirements for other therapies of anemia (e.g., iron, ESA, or BTx) and 63 % decline in the BTx requirements alone. However, all-cause MR (21 vs 18 %), CVS events (23 vs 21 %), and total serious adverse events (57 vs 54 %) were increasing among ptns receiving roxadustat as compared to ptns on placebo. Serious untoward effects that were more commonly reported with roxadustat may include . Similar observations have been seen in smaller phase 3 studies from the European Union, China, and Japan. Other HIF PHIs agents under clinical trials include . As HIF pathway is regulating or interacting with several biologic processes, there is wide interest in the non-EPO adverse effects that may include - to certain degree – a higher risk of , among others still requiring long-term evaluation of the treated ptns. None of the above members have been approved yet in the US.